Skip to search formSkip to main contentSkip to account menu

WHO Central Nervous System Grade II

Known as: Grade 2, Grade II, WHO Grade II 
Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors
Carbonic anhydrase related proteins (CARPs) VIII, X and XI functionally differ from the other carbonic anhydrase (CA) enzymes… 
2014
2014
OP22SOCIAL DEPRIVATION SHORTENS SURVIVAL IN PATIENTS WITH HIGH GRADE GLIOMA.
INTRODUCTION: Low socioeconomic status is associated with increased frequency of chronic conditions, a higher frequency of mental… 
2014
2014
QL-04FACTORS ASSOCIATED WITH SUICIDAL IDEATION IN CLINICALLY DISTRESSED ADULT GLIOMA PATIENTS.
OBJECTIVE: During patient care, it is critical to identify the glioma patients who are experiencing suicidal ideation among those… 
Review
2013
Review
2013
The molecular biology of WHO grade II gliomas.
The WHO grading scheme for glial neoplasms assigns Grade II to 5 distinct tumors of astrocytic or oligodendroglial lineage… 
Review
2013
Review
2013
The Molecular Biology of Diffuse Low-Grade Gliomas
The World Health Organization (WHO) grading scheme for glial neoplasms assigns grade II to three infiltrating (non-circumscribed… 
2010
2010
Measurement of glycine in a brain and brain tumors by means of 1H MRS.
AIM Evaluation of a peak at 3.55 ppm in a long echo time (TE) recognized as glycine (Gly) in the WHO grade II gliomas and central… 
2008
2008
Computational Modelling of the WHO Grade II Glioma Dynamics: Principles and Applications to Surgical Strategy
2008
2008
Revue générale Radiothérapie des tumeurs gliales de l ’ adulte : actualités et perspectives Radiotherapy of adult glial tumors : New developments and perspectives
Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors. The prognosis of these tumors depends on… 
Highly Cited
2000
Highly Cited
2000
Differential expression of S100 calcium‐binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours
The computer‐assisted microscopic analysis of Feulgen‐stained nuclei enabled us to identify two subgroups of astrocytomas (WHO… 
Highly Cited
1999
Highly Cited
1999
Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas and Glioblastomas are Characterized by a Differential Expression of S100 Proteins
The levels of expression of the S100A1, S100A2, S100A3, S100A4, S100A5, S100A6 and S100B proteins were immunohistochemically… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)